Aadia Rana is an Infectious Disease physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 98 publications with 1,108 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 6th Ave S
Birmingham, AL 352331801
Telephone
800-822-8816Registry record last updated 29 Jun 2023.
Clinical trials
- The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20221 payment
- Janssen Scientific Affairs, LLCProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
69.5%Gabapentinoids40.7%Gabapentin100%Part D≥11 patientsOpioid Agonist18.6%Oxycodone-Acetaminophen50%Methadone Hcl50%Part D<11 patients+ 1 more class in this area
Cardiovascular
19.5%Statin10.2%Atorvastatin Calcium100%Part D<11 patientsCalcium channel blocker9.3%Amlodipine Besylate100%Part D<11 patientsAnti-infectives
11%Lipopeptide Antibacterial11%Daptomycin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Drive to Zero: Developing a digital cohort to understand the drivers of non-sustained viral suppression in the Deep South
University of Alabama at Birmingham
FY2026$1,311,673UH3AI176566 - A type 2 hybrid effectiveness-implementation trial to evaluate a population health combination intervention to meet HIV testing, linkage, and viral suppression goals in coastal Alabama
University of Alabama at Birmingham
FY2026$782,394R01AI169671 - Implementation and Community Sciences Core (Core D)
University of Alabama at Birmingham
FY2026$257,523P30AI027767
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Policymaker Perspectives on Implementation Determinants of Rapid ART and Same-Day PrEP in Seven Priority Jurisdictions for Ending the HIV Epidemic: A Multisite Qualitative Study
JAIDS Journal of Acquired Immune Deficiency Syndromes
2025 - Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White–Funded Clinics: Results From a Multisite Survey
JAIDS Journal of Acquired Immune Deficiency Syndromes
2025 - Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges
Current Opinion in HIV and AIDS
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”